Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.25 2.27% 2.22% 100K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
LXRX | $1.62 -5.26% -5.56% 3.5M
|
Health Technology
|
| O: 0.36%
H: 0.32%
C: -10.64%
disease kidney control treatment diabetes study
The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On
Published: 2024-03-11 (Crawled : 21:00) - prnewswire.com
DVA | News | $133.91 1.05% -1.54% 400K
|
Health Services
|
| O: 0.01%
H: 2.86%
C: 2.48%
disease association diabetes
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 7.33%
H: 3.1%
C: -13.66%
first disease cell agreement therapy
Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
disease dupixent skin
Study on Foot-and-Mouth Disease Virus Results in Submission for Additional EPA Label
Published: 2024-03-11 (Crawled : 14:00) - globenewswire.com
TOMZ | $0.6 2.96% 1.5K
|
Producer Manufacturing
|
| O: -0.01%
H: 1.37%
C: -1.64%
label disease virus results study submission
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
| Email alert
Add to watchlist
wegovy obesity disease approved risk cardiovascular
Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China
Published: 2024-03-08 (Crawled : 02:00) - prnewswire.com
SILK | $17.64 1.32% 1.3% 480K
|
Health Technology
|
| O: 1.75%
H: 2.34%
C: 0.86%
disease medical china
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
Published: 2024-03-07 (Crawled : 15:30) - globenewswire.com
VAXX | $0.2 -25.82% -34.8% 2M
|
|
| O: -1.42%
H: 37.63%
C: 11.15%
disease positive parkinson’s trial
Cell culture market size to increase by USD 17.74 billion, The increase in infectious disease drives the market growth, Technavio
Published: 2024-03-06 (Crawled : 22:00) - prnewswire.com
CMI | $292.7 0.79% 0.0% 780K
|
Producer Manufacturing
|
| O: -0.13%
H: 1.4%
C: -2.52%
disease cell market
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
CGTX | News | $2.02 8.6% 7.92% 140K
|
|
| O: -1.9%
H: 1.94%
C: -0.97%
ct1812 disease alzheimer’s treatment therapeutics
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -4.66%
H: 6.67%
C: 3.56%
gt-0228 conference disease treatment parkinson’s therapeutics
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
TLSA | News | $0.7501 -0.46% -0.47% 2.5M
|
Health Technology
|
| O: -2.45%
H: 12.35%
C: 12.35%
disease anti-cd3 life alzheimer’s presentation sciences
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published: 2024-03-05 (Crawled : 10:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -1.33%
H: 0.46%
C: -1.27%
disease kidney risk trial diabetes flow
BD Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease
Published: 2024-03-04 (Crawled : 00:00) - biospace.com/
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: -0.4%
H: 0.92%
C: 0.55%
disease international treatment study
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
QTRX | $16.085 -1.32% -1.34% 410K
|
Health Technology
|
| O: 3.7%
H: 1.64%
C: 0.25%
fda device disease test granted alzheimer’s designation
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $364.27 37.56% 850
|
Consumer Non-Durables
|
| O: -0.59%
H: 0.27%
C: -1.83%
PPRUY | News | $36.96 -0.11% 220K
|
Manufacturing
|
| O: -1.85%
H: 0.2%
C: -0.07%
PCVX | $60.89 -1.15% -1.17% 670K
|
Health Technology
|
| O: 0.2%
H: 0.18%
C: -0.42%
STRO | $3.73 -1.06% -1.07% 720K
|
Health Technology
|
| O: 0.2%
H: 1.81%
C: -3.43%
vax-24 disease pneumococcal study
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 2.47%
H: 5.02%
C: -8.03%
disease biotech million grant therapeutics therapy
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
Published: 2024-03-04 (Crawled : 12:30) - globenewswire.com
ZVRA | $4.59 0.44% 0.44% 140K
|
n/a
|
| O: -5.79%
H: 0.15%
C: -6.75%
fda disease update treatment pdufa therapeutics
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
RNA | News M | $25.12 3.97% 3.82% 860K
|
Health Technology
|
| O: 2.44%
H: 0.15%
C: -8.45%
disease positive key trial living
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.